Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 945 across all filing types
Latest filing 2025-05-15 Earnings Release
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the quarter and full year ended March 31, 2025, for Neuland Laboratories Limited. It includes a financial summary with key figures such as total income, EBITDA, PAT, and EPS for Q4FY25 and FY25, along with commentary from the CEO and Managing Director. The document also mentions an upcoming earnings call to discuss these results. The content is typical of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights. The document is about 5,415 characters, which is consistent with a press release length rather than a full detailed report. There is no indication that this is a full Annual Report (10-K) or Interim Report (IR), nor is it a transcript of the earnings call (CT). Therefore, the appropriate classification is Earnings Release (ER). FY 2025
2025-05-15 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed announcement from Neuland Laboratories Limited regarding the outcome of a Board Meeting held on May 15, 2025. It includes approval of audited financial results for the year ended March 31, 2025, along with the auditor's report containing an unmodified opinion. The document also covers the recommendation of a final dividend, re-appointment of a Whole Time Director, approval of the Annual General Meeting date, record date for dividend eligibility, and appointment of secretarial auditors. The presence of audited financial results, auditor's report, and comprehensive financial information for the fiscal year indicates this is a full annual report document. The length of the document (15,000 characters) and the inclusion of detailed financial statements and audit opinions confirm it is not merely an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2025-05-15 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from Neuland Laboratories Limited regarding the outcome of a Board Meeting held on May 15, 2025. It includes approval of audited financial results for the year ended March 31, 2025, along with the auditor's report from MSKA & Associates with an unmodified opinion. The document also covers the recommendation of a final dividend, re-appointment of a Whole Time Director, approval of the Annual General Meeting date, record date for dividend, and appointment of secretarial auditors. The presence of audited financial results and the auditor's report indicates this is a comprehensive financial report for the full fiscal year. The document is lengthy (15,000 characters) and contains substantive financial data and audit opinions, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K) rather than a simple announcement or regulatory filing. Hence, the classification is Annual Report (10-K) with high confidence. FY 2025
2025-05-15 English
Retirement
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the completion of tenure of an Independent Director, Dr. Nirmala Murthy, and her consequent cessation as a Director of the company. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosures about changes in the board of directors. The content is about a change in senior management/board composition rather than financial results, audit, or other report types. The document length is short and focused solely on this management change. Therefore, it fits the category of Board/Management Information (MANG).
2025-05-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter dated May 5, 2025, addressed to stock exchanges, informing about the schedule of the Q4 FY 2025 earnings call for Neuland Laboratories Limited. It references the upcoming announcement of financial results on May 15, 2025, and provides details for the earnings call event. The document does not contain any financial data or results itself, but rather serves as an intimation or notice about the earnings call. The document length is short (2464 characters), and it explicitly states the earnings call schedule and that results will be announced later. Therefore, this document is an announcement related to an earnings call, not the earnings release or transcript itself. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about an event (earnings call) without substantive financial data or transcript content.
2025-05-05 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing them about a recent FDA inspection and issuance of Form 483 with one observation. It is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers material event disclosures. The document does not contain any financial data, detailed report, or analysis. It is a regulatory announcement informing the market about a compliance event. Given the short length (1220 characters) and the nature of the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-05-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.